Inflation Reduction Act ushers in new era of lower insulin prices

15 March 2023

The impact of US President Joe Biden's Inflation Reduction Act is beginning to be felt, as Danish diabetes giant Novo Nordisk (NOV: N) announced plans to slash the cost of insulin.

The legislation, a signature achievement for the White House, caps the cost of the drug for Medicare recipients at just $35 for a month’s supply, although this excludes uninsured people.

The move comes after insulin rival Eli Lilly (NYSE: LLY) revealed it would cut the price of its most popular insulin products by a similar amount, starting from the latter part of the year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK